Venaxis Completes Patient Enrollment in Pivotal Clinical Trial of APPY1™ Test

Venaxis Completes Patient Enrollment in Pivotal Clinical Trial of APPY1™ Test

PR Newswire

CASTLE ROCK, Colo., Jan. 24, 2014

CASTLE ROCK, Colo., Jan. 24, 2014 /PRNewswire/ --Venaxis, Inc. (Nasdaq:
APPY), an in vitro diagnostic company focused on obtaining FDA clearance and
commercializing its CE Marked APPY1 Test, a rapid, multiple biomarker-based
assay for identifying patients that are at low risk for appendicitis, today
announced completion of patient enrollment in its pivotal clinical study of
the APPY1 Test in the United States. Venaxis expects to announce top-line
data following the required patient follow-up period and subsequent database
lock and required analysis of the data. The study enrolled patients at
approximately 27 hospital sites across the United States, and the pivotal data
will be based on approximately 2,000 net evaluable patients.

Steve Lundy, President and Chief Executive Officer of Venaxis™, commented,
"Completing this significant pivotal U.S. study is a major milestone for
Venaxis and we look forward to reporting the data when it is available. We
will work to finalize our 510(k) and final data package for FDA submission at
or near the end of the first quarter, assuming positive data. In the
meantime, we remain committed to our diligent market development efforts and
expect to be well positioned to launch the APPY1 Test in the United States
upon receipt of clearance."

About Venaxis, Inc.

Venaxis, Inc. is an in vitro diagnostic company focused on the clinical
development and commercialization of its CE Marked APPY1 Test, the Company's
rapid, protein biomarker-based assay for appendicitis. This unique
appendicitis test has projected high sensitivity and negative predictive value
and is being developed to aid in the identification of patients at low risk
for acute appendicitis, allowing for more conservative patient management.
The APPY1 Test is being developed initially for pediatric, adolescent and
young adult patients with abdominal pain, as this population is at the highest
risk for appendicitis and has the highest risk of long-term health effects
associated with CT imaging. While FDA clearance is being sought, an initial
launch for the APPY1 Test is ongoing in select European countries. For more
information, visit

Forward-Looking Statements

This press release includes "forward-looking statements" of Venaxis, Inc.
("Venaxis") as defined by the Securities and Exchange Commission ("SEC"). All
statements, other than statements of historical fact, included in this press
release that address activities, events or developments that Venaxis believes
or anticipates will or may occur in the future are forward-looking statements.
These statements are based on certain assumptions made based on experience,
expected future developments and other factors Venaxis believes are
appropriate in the circumstances. Such statements are subject to a number of
assumptions, risks and uncertainties, many of which are beyond the control of
Venaxis. Investors are cautioned that any such statements are not guarantees
of future performance. Actual results or developments may differ materially
from those projected in the forward-looking statements as a result of many
factors, including our ability to successfully complete required product
development and modifications in a timely and cost effective manner, complete
clinical trial activities for the APPY1  Test required for FDA submission,
obtain FDA clearance or approval, maintain CE Marking, cost effectively
manufacture and generate revenues from the APPY1  Test at a profitable price
point, execute agreements required to successfully advance the company's
objectives, retain the management team to advance the products, overcome
adverse changes in market conditions and the regulatory environment, obtain
and enforce intellectual property rights, and realize value of intangible
assets. Furthermore, Venaxis does not intend (and is not obligated) to update
publicly any forward-looking statements. The contents of this press release
should be considered in conjunction with the risk factors contained in
Venaxis' recent filings with the SEC, including its Form 10-Q for the quarter
ended June 30, 2013.

Venaxis and APPY1 are trademarks of Venaxis, Inc.

For Investors and Media:
Tiberend Strategic Advisors, Inc.

Joshua Drumm, PhD; (212) 375-2664

Claire Sojda; (212) 375-2686

SOURCE Venaxis, Inc.

Press spacebar to pause and continue. Press esc to stop.